CLINICAL STUDIES OF PRIMARY ANGLE CLOSURE GLAUCOMA

ＣＬＩＮＩＣＡＬＳＴＵＤＩＥＳＯＦＰＲＩＭＡＲＹＡＮＧＬＥＣＬＯＳＵＲＥＧＬＡＵＣＯＭＡＷａｎｇＮｉｎｇｌｉ王宁利，ＺｈｏｕＷｅｎｂｉｎ周文炳，ＹｅＴｉａｎｃａｉ叶天才，ＷｕＺｈｏｎｇｙａｏ吴中耀，ＬｉｕＨｕａ刘华ＣＬＩＮＩＣＡＬＳＴＵＤＩＥＳＯＦＰ...     

端粒酶抑制剂对葡萄膜黑色素瘤细胞生长的抑制作用

Objective To study the restrain effects of two telomerase inhibitors included IFN-α2b (interferon-α2b)and CDDP(cisplatin;cis-dichlorodiamine platinum)to uveal melanoma cells of human eyes,and to provide theory bases for chemotherary of uveal melanoma.Methods Applied IFN-α2b and CDDP to the primary cultured uveal melanoma cells of human eyes individually with different concentration and duration,and compared with control group.Morphological changes were observed by inverted optical and electronic microscope,and the restrain effects were detected by MTT.Results More and more morphological changes of restraint and apoptosis of cells were observed with the increasing concentration and duration of IFN-α 2b and CDDP.When action durations were 72 h.the cells were inhibited with the concentration more than 500 IU/ml(IFN-α 2b)and 1.00 mg/L(CDDP)respectively.The cells restrain rates were(66.1±4.7)%and(74.0+3.3)%with the concentration more than 5000 IU/ml(IFN-α2b)and 10 mg/L (CDDP),and the rates were higher than before(P<0.001).When concentrations were 5000 IU/ml(IFN-α2b)and 10.00 mg/L(CDDP),cells were inhibited at 48 h and the restrain rates were(67.9±8.1)%and(76.5±1.61%at 72 h,respectively,(P相似文献   

端粒酶抑制剂对葡萄膜黑色素瘤细胞生长的抑制作用

Objective To study the restrain effects of two telomerase inhibitors included IFN-α2b (interferon-α2b)and CDDP(cisplatin;cis-dichlorodiamine platinum)to uveal melanoma cells of human eyes,and to provide theory bases for chemotherary of uveal melanoma.Methods Applied IFN-α2b and CDDP to the primary cultured uveal melanoma cells of human eyes individually with different concentration and duration,and compared with control group.Morphological changes were observed by inverted optical and electronic microscope,and the restrain effects were detected by MTT.Results More and more morphological changes of restraint and apoptosis of cells were observed with the increasing concentration and duration of IFN-α 2b and CDDP.When action durations were 72 h.the cells were inhibited with the concentration more than 500 IU/ml(IFN-α 2b)and 1.00 mg/L(CDDP)respectively.The cells restrain rates were(66.1±4.7)%and(74.0+3.3)%with the concentration more than 5000 IU/ml(IFN-α2b)and 10 mg/L (CDDP),and the rates were higher than before(P<0.001).When concentrations were 5000 IU/ml(IFN-α2b)and 10.00 mg/L(CDDP),cells were inhibited at 48 h and the restrain rates were(67.9±8.1)%and(76.5±1.61%at 72 h,respectively,(P相似文献   

甲状腺相关眼病患者血清中抵抗素水平的测定

目的检测甲状腺相关眼病（TAO）患者血清中抵抗素的表达水平。方法 TAO患者血清样本来自有典型临床症状且近3个月内未服用糖皮质激素和免疫抑制剂的TAO患者35例,按CAS临床活动度评分标准将其分为2组：非活动期（CAS〈4）18例和活动期（CAS≥4）17例,另外选取正常对照组15例。使用ELISA法检测血清中抵抗素蛋白的表达情况。结果活动期与非活动期TAO患者血清中抵抗素水平分别为（12.103±5.042）mg/L和（13.470±3.749）mg/L,差异无统计学意义（t=0.906,P=0.371）;正常对照组血清抵抗素水平为（21.894±10.589）mg/L,非活动期、活动期TAO组血清抵抗素水平分别为（12.103±5.042）mg/L和（13.470±3.749）mg/L,均较正常对照组明显下降（t=3.074,P=0.004;t=3.485,P=0.001）。男女患者血清中抵抗素水平分别为（13.175±4.483）mg/L和（12.335±4.511）mg/L,差异无统计学意义（t=0.552,P=0.585）。随着年龄的增加,血清中抵抗素水平逐渐升高,各年龄组间比较差异有统计学意义（F=24.978,P=0.000）。结论 TAO患者血清中抵抗素水平低于正常人,说明影响血清中抵抗素水平的仍是甲状腺激素,并且血清中抵抗素水平随年龄的增加而升高。     

视网膜母细胞瘤的生存率和预后因素研究

目的研究视网膜母细胞瘤(Rb)的生存率及预后因素。方法随访1997～2001年102例Rb患者的生存状况,进行Rb的生存率和相关预后因素分析。结果随访102例Rb患者,平均随访时间为45.2个月。81例存活(79.4%),21例死亡(20.6%);1、3、5年的生存率分别为87.25%、81.37%和78.79%。单眼、双眼患者生存率分别为84.52%和54.55%,差异有统计学意义(P<0.01);病程≤6个月的生存率为85.36%,病程>6个月的生存率为58.33%,两者差异有统计学意义(P<0.01);12例眶组织侵犯,存活5例,死亡7例,生存率为41.67%,眶组织未受侵犯组生存率为83.78%,两者差异有统计学意义(P<0.01);10例进行眼球保守治疗,5例成功;93例Ⅰ期行眼球摘除术的患者中,84例行Ⅰ期义眼座植入术,其中73例(86.9%)存活,11例(13.1%)死亡。结论 102例Rb患者42个月后生存率达到78.72%。双眼患者、病程>6个月和眶组织侵犯者预后较差,生存率低。Rb患者有一定的保守治疗成功率,Rb患者行眼球摘除术时,可选择联合行Ⅰ期义眼座植入。     

端粒酶抑制剂对葡萄膜黑色素瘤细胞生长的抑制作用

Objective To study the restrain effects of two telomerase inhibitors included IFN-α2b (interferon-α2b)and CDDP(cisplatin;cis-dichlorodiamine platinum)to uveal melanoma cells of human eyes,and to provide theory bases for chemotherary of uveal melanoma.Methods Applied IFN-α2b and CDDP to the primary cultured uveal melanoma cells of human eyes individually with different concentration and duration,and compared with control group.Morphological changes were observed by inverted optical and electronic microscope,and the restrain effects were detected by MTT.Results More and more morphological changes of restraint and apoptosis of cells were observed with the increasing concentration and duration of IFN-α 2b and CDDP.When action durations were 72 h.the cells were inhibited with the concentration more than 500 IU/ml(IFN-α 2b)and 1.00 mg/L(CDDP)respectively.The cells restrain rates were(66.1±4.7)%and(74.0+3.3)%with the concentration more than 5000 IU/ml(IFN-α2b)and 10 mg/L (CDDP),and the rates were higher than before(P<0.001).When concentrations were 5000 IU/ml(IFN-α2b)and 10.00 mg/L(CDDP),cells were inhibited at 48 h and the restrain rates were(67.9±8.1)%and(76.5±1.61%at 72 h,respectively,(P相似文献   

重组人抵抗素对甲状腺相关眼病患者眼眶前脂肪细胞增殖的影响

通过旁分泌影响眼眶内前脂肪细胞的增殖,从而参与TAO的发病过程.     

体外视网膜母细胞瘤细胞对不同化疗药物的敏感性分析

[目的]研究视网膜母细胞瘤(retinoblastma,RB)细胞对化疗药物的体外敏感性,以制定合理的RB临床个体化化疗方案.[方法]应用3-(4,5)-双甲基-2噻唑-(2,5)-二甲基溴化四氮唑蓝(MTT)体外药敏法,测定35例RB患儿瘤细胞对常用的阿霉素、长春新碱、鬼臼乙叉苷、卡铂、甲氨喋呤、放线菌素D和噻替哌共7种化疗药物的敏感性.[结果]RB的药敏可评价率是86.7%.同一种药物对不同的肿瘤细胞有不同的抑制率,7种药物的最高抑制率是卡铂(91.8%)、噻替哌(90.7%)、放线菌素D(89.7%)、鬼臼乙叉苷(88.4%)、阿霉素(86.61%)、甲氨喋呤(58.66%)、长春新碱(54.95%);最低的直接抑制率均是0.[结论]不同RB个体的瘤细胞对不同的化疗药物有不同的敏感性,体外药敏试验筛选敏感化疗药物对临床RB个体化治疗有应用价值.     

肌炎型特发性眼眶炎性假瘤

目的探讨肌炎型眼眶特发性炎性假瘤的临床特点.方法回顾分析我院1978年1月～1999年12月特发性眼眶炎性假瘤病例,每例均有完整的临床特点、影像表现、诊断和治疗结果等记录.随访时间为1周到9年(平均4个月).结果　209例眼眶特发性炎性假瘤中,16例(8%)属于肌炎型眼眶特发性炎性假瘤.其中男6例,女10例;右眼6例,左眼7例,双眼3例;平均就诊年龄39岁.以眼球运动受限与斜视(87.5%)、复视(68.8%)、眼球突出(62.5%)为最常见表现,眼部充血(43.8%)和疼痛(43.8%)是与其它类型斜视不同的重要特点.各条眼外肌中,上直肌受累最常见(62.5%),其次为外直肌(43.8%),内直肌(31%)和下直肌(31%).经全身激素或激素联合局部放射治疗后,治愈率为56%,有效率为75%,复发率为75%.结论肌炎型是特发性眼眶炎性假瘤中较少见的临床亚型之一,以上直肌受累最常见,其次为外直肌、内直肌与下直肌.全身激素或激素联合放射治疗的治愈率只有56%,而复发率高达75%.如何提高治愈率与减少复发率是今后努力的方向.     

结膜下注射卡铂和环孢素联合治疗视网膜母细胞瘤的实验研究

【目的】观察结膜下注射卡铂治疗视网膜母细胞瘤(RB)的疗效和环孢素(CsA)对卡铂治疗RB的增效作用。【方法】40只RB成瘤裸鼠分8组(G1～G8),对照组(G1)结膜下注射生理盐水,全身用药组(G2)腹腔内注射卡铂350μg+环孢素1.0mg,G3～G5组及G6～G8组分别结膜下注射卡铂100、200、350μg及卡铂100、200、350μg+CsA1.0mg,每周2次共3周。每天裂隙灯观察前房肿瘤情况并照相,第6周取眼球及结膜、巩膜作病理及图像处理,计算肿瘤面积及肿瘤抑瘤率。【结果】G2、G3、G6组肿瘤生长较G1组减缓,肿瘤未能控制。G4组肿瘤生长延缓,肿瘤控制率为40%。G5及G7组肿瘤无继续增大,部分肿瘤体积减少,肿瘤控制率和治愈率为60%和20%,G8组肿瘤全部控制,肿瘤控制率和治愈率为20%和80%,肿瘤基本消失。结膜下注射部位结膜和巩膜检查未见异常。图像处理及统计学分析显示,G3、G4、G6肿瘤面积和抑瘤率与G2之间无显著性差异(P>0.05),G5、G7、G8组肿瘤面积和抑瘤率与G2之间有显著性差异(P<0.05)。【结论】结膜下注射卡铂能在较低剂量下抑制RB生长,加用CsA能提高卡铂治疗RB疗效。结膜下联合注射卡铂和CsA是一种安全有效的RB化疗方法。